文献速递前列腺癌

将浸润性筛状和导管内癌纳入2014级组以改进前列腺癌活检分级

Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
PubMed 文献 · Eur Urol · 2019-08-19

研究对1031例筛查发现的前列腺癌患者的活检标本重新评审当前级组(GG)和筛状/导管内癌(CR/IDC),提出筛状分级(cGrade)。cGrade对疾病特异性生存的区分度优于GG(C指数0.79 vs 0.76),对无转移生存的区分度也优于GG(0.79 vs 0.77),尤其影响当前GG2患者的决策。

要点

  • cGrade对疾病特异性生存的区分度优于GG:C指数0.79 vs 0.76。
  • cGrade对无转移生存的区分度优于GG:C指数0.79 vs 0.77。
  • cGrade对根治性前列腺切除术后和放疗后的生化复发无生存的区分度与GG相似。

核心结论

  • cGrade是一种简单的前列腺癌分级修改,对疾病特异性生存和无转移生存的区分度优于GG,尤其影响当前GG2前列腺癌男性的决策。

研究设计与样本

  • 对1993年至2000年间1031例筛查发现的前列腺癌男性的所有前列腺活检标本进行评审,评估当前GG(1至5级)和CR/IDC。
  • 共406例患者接受根治性前列腺切除术,508例接受放疗,108例接受监测,8例接受激素治疗,1例治疗未知。
  • 中位随访15.1年(四分位距10.9-19.7年),比较疾病特异性生存、无转移生存和生化复发无生存,使用Harrell C统计量。

主要发现

  • 活检GG分布为486例GG1、310例GG2、104例GG3、64例GG4、67例GG5;cGrade分布为738例cGrade1、102例cGrade2、91例cGrade3、58例cGrade4、42例cGrade5。
  • cGrade对疾病特异性生存的区分度优于GG:C指数0.79(95% CI 0.74-0.83) vs 0.76(95% CI 0.71-0.82)。
  • cGrade对无转移生存的区分度优于GG:C指数0.79(95% CI 0.74-0.84) vs 0.77(95% CI 0.72-0.82)。
  • cGrade和GG对根治性前列腺切除术后和放疗后的生化复发无生存的区分度相似。

关键数值与推荐

  • cGrade定义:若存在CR/IDC,则cGrade等于GG;若不存在,则cGrade等于GG减1;若导管内癌不存在,GG1对应cGrade1。

临床怎么用

  • 作者认为cGrade是一种简单的前列腺癌分级修改,对疾病特异性生存和无转移生存的区分度优于GG,尤其影响当前GG2前列腺癌男性的决策。

局限性

  • 本研究局限性包括20世纪90年代使用的诊断策略(如六针活检)和治疗策略不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Grade groups (GGs) are an important parameter for therapeutic decision making in prostate cancer (Pca) patients. Invasive cribriform and/or intraductal carcinoma (CR/IDC) has an independent prognostic value for disease outcome, but are not included in the GG limiting their clinical use. OBJECTIVE: To perform a proof-of-principle study incorporating CR/IDC in the current GG. DESIGN, SETTING, AND PARTICIPANTS: All prostate biopsies of 1031 men with screen-detected Pca between 1993 and 2000 were reviewed for the current GG (ranging from 1 to 5) and CR/IDC. The cribriform grade (cGrade) was equal to the GG if CR/IDC was present and GG minus 1 if not. GG1 was cGrade1 if intraductal carcinoma was absent. INTERVENTION: Biopsy review for GG and CR/IDC. A total of 406 patients had received radical prostatectomy (RP), 508 radiotherapy (RT), 108 surveillance, and eight hormonal therapy, and the treatment was unknown for one patient. Outcome measurements and statistical analysis disease-specific survival (DSS), metastasis-free survival (MFS), and biochemical recurrence-free survival (BCRFS) after 15.1 yr (interquartile range 10.9-19.7 yr) follow-up were compared using Harrell's C-statistic. RESULTS AND LIMITATIONS: The biopsy GGs were 486 GG1, 310 GG2, 104 GG3, 64 GG4, and 67 GG5; cGrade distributions were 738 cGrade1, 102 cGrade2, 91 cGrade3, 58 cGrade4, and 42 cGrade5. The cGrade had a better discriminative value than the GG for DSS (C-index 0.79; 95% confidence interval 0.74-0.83 vs 0.76; 0.71-0.82) and MFS (0.79; 0.74-0.84 vs 0.77; 0.72-0.82). The discriminative value for BCRFS after RP and RT was similar for both models. Different diagnostic, such as use of sextant biopsies, and therapeutic strategies in the 1990s are the limitations of this study. CONCLUSIONS: The cGrade is a simple Pca grade modification with better discriminative values for DSS and MFS than the GG, particularly impacting decision making in men with current GG2 Pca. PATIENT SUMMARY: Microscopic grading is an important factor for decision making in prostate cancer (Pca) patients. We show that a simple grade modification better predicts Pca outcome and might improve treatment choices.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. van Leenders GJLH, Kweldam CF, Hollemans E, et al. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. Eur Urol. 2019. PMID: 31439369. doi:10.1016/j.eururo.2019.07.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。